Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Agenus Inc. (AGEN)

2.79   -0.18 (-6.06%) 12-05 16:00
Open: 2.95 Pre. Close: 2.97
High: 2.95 Low: 2.67
Volume: 4,001,995 Market Cap: 850(M)

Technical analysis

as of: 2022-12-06 8:15:59 AM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.93     One year: 4.59
Support: Support1: 2.52    Support2: 2
Resistance: Resistance1: 3.36    Resistance2: 3.93
Pivot: 2.92
Moving Average: MA(5): 2.74     MA(20): 2.77
MA(100): 2.61     MA(250): 2.49
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 43.7     %D(3): 46.8
RSI: RSI(14): 51.5
52-week: High: 3.61  Low: 1.25
Average Vol(K): 3-Month: 4,822 (K)  10-Days: 3,345 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AGEN ] has closed above bottom band by 33.2%. Bollinger Bands are 5.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.96 - 2.97 2.97 - 2.98
Low: 2.63 - 2.65 2.65 - 2.67
Close: 2.76 - 2.79 2.79 - 2.82

Company Description

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Headline News

Tue, 06 Dec 2022
More Talent Joins Indonesia’s ‘Agency’ – ATF Bulletin - Variety

Fri, 02 Dec 2022
Agenus Inc. (NASDAQ:AGEN) Short Interest Up 18.5% in November - MarketBeat

Thu, 01 Dec 2022
Laporte documentary: City defender’s special return to his hometown Agen - Manchester City FC

Wed, 30 Nov 2022
Agenus Inc (AGEN) is lower by -14.14% in a Week, Should You Accumulate? - InvestorsObserver

Sat, 19 Nov 2022
World Cup winner Jantjies to join second division Agen - FRANCE 24 English

Fri, 18 Nov 2022
Is Agenus Inc (AGEN) a Good Buy in the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 305 (M)
% Held by Insiders 2.5049e+008 (%)
% Held by Institutions 9.6 (%)
Shares Short 16,920 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.7198e+008
EPS Est Next Qtl -0.28
EPS Est This Year -1.13
EPS Est Next Year -1.29
Book Value (p.s.) 0
Profit Margin (%) -238.6
Operating Margin (%) -198.8
Return on Assets (ttm) -25.8
Return on Equity (ttm) -1
Qtrly Rev. Growth 8.99e+007
Gross Profit (p.s.) -70
Sales Per Share 684.84
EBITDA (p.s.) 8.73769e+007
Qtrly Earnings Growth 0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -151 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -51.82

Stock Dividends

Dividend 0
Forward Dividend 1.899e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.